Engineering Red Blood Cell Membrane-Coated PLGA Nanoparticles for Kahweol Delivery: Formulation Development and Pharmacokinetic Assessment
Molecules · 14.09.2026 · 31 (18) · 3239
DOI: 10.3390/molecules31183239 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 14.09.2026. Verfasst von Okan Ali Aksoy und 9 weiteren Autor:innen. Beteiligte Einrichtung: Gulhane Institute of Health Sciences, University of Health Sciences, Ankara 06018, Türkiye. Hauptthemen laut MEDLINE: Polylactic Acid-Polyglycolic Acid Copolymer, Nanoparticles, Diterpenes, Erythrocyte Membrane. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kahweol is an active diterpene with anti-inflammatory, antioxidant, and anticancer properties; however, its use may be limited by unfavorable pharmacokinetic characteristics. This study aimed to develop kahweol-loaded poly(lactic-co-glycolic acid) (PLGA) and red blood cell membrane-coated PLGA (RBC-PLGA) nanoparticles and evaluate their in vitro release behavior and in vivo pharmacokinetic profiles. Kahweol-loaded PLGA nanoparticles were prepared using the emulsification-solvent evaporation method and subsequently coated with rabbit erythrocyte membranes, a type of blood cell membrane, to obtain RBC-PLGA nanoparticles. Particle size, zeta potential, morphology, and encapsulation efficiency were characterized. In vitro release studies were performed using the dialysis bag method. Pharmacokinetic profiles of free kahweol, kahweol-loaded PLGA, and kahweol-loaded RBC-PLGA nanoparticles were evaluated in rabbits following intravenous administration (0.5 mg/kg), and plasma kahweol concentrations were analyzed by LC-MS/MS. PLGA and RBC-PLGA nanoparticles showed high encapsulation efficiency (>90%) and sustained biphasic release compared with the rapid burst release of free kahweol. Pharmacokinetic analysis demonstrated that PLGA and RBC-PLGA nanoparticles reduced peak plasma concentrations and prolonged systemic exposure. Among the nanoparticles, RBC-PLGA exhibited the most prolonged pharmacokinetic profile, with delayed time to maximum plasma concentration (Tmax), extended half-life, and increased overall exposure. The nanoparticles improved the pharmacokinetic profile of kahweol by enabling sustained release and prolonged systemic exposure, supporting their potential as delivery platforms for future applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gulhane Institute of Health Sciences, University of Health Sciences, Ankara 06018, Türkiye.
- Department of Pharmacology, Gulhane Faculty of Pharmacy, University of Health Sciences, Ankara 06018, Türkiye.
- Department of Pharmaceutical Technology, Gulhane Faculty of Pharmacy, University of Health Sciences, Ankara 06018, Türkiye.
- Department of Pharmaceutical Biotechnology, Gulhane Faculty of Pharmacy, University of Health Sciences, Ankara 06018, Türkiye.
ORCID-Profile: Okan Ali Aksoy, Yagmur Okcay, Özgür Eşim
Zitieren
APA
Aksoy, O. A., Okcay, Y., Solmaz, A. E., Kılıç, K., Göksel, B. A., Eser, B., Eşim, Ö., Vural, İ. M., Savaşer, A., & Özkan, Y. (2026). Engineering Red Blood Cell Membrane-Coated PLGA Nanoparticles for Kahweol Delivery: Formulation Development and Pharmacokinetic Assessment. Molecules, 31(18), 3239. https://doi.org/10.3390/molecules31183239
Vancouver
Aksoy OA, Okcay Y, Solmaz AE, Kılıç K, Göksel BA, Eser B, et al. Engineering Red Blood Cell Membrane-Coated PLGA Nanoparticles for Kahweol Delivery: Formulation Development and Pharmacokinetic Assessment. Molecules. 2026;31(18):3239. doi:10.3390/molecules31183239
BibTeX
@article{Aksoy2026,
author = {Aksoy, Okan Ali and Okcay, Yagmur and Solmaz, Alperen Enes and Kılıç, Kübra and Göksel, Berk Alp and Eser, Burcu and Eşim, Özgür and Vural, İsmail Mert and Savaşer, Ayhan and Özkan, Yalçın},
title = {Engineering Red Blood Cell Membrane-Coated PLGA Nanoparticles for Kahweol Delivery: Formulation Development and Pharmacokinetic Assessment},
journal = {Molecules},
year = {2026},
volume = {31},
number = {18},
pages = {3239},
doi = {10.3390/molecules31183239}
}
EUVIMED